A Study of Pneumococcal Pneumonia

Davies, Daniel; Hodgson, H; Whitby, LionelE.H.

doi:10.1016/s0140-6736(00)56771-3

Cited by 8 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More-recent studies show that the effects of age and bacteremia on outcome are still important today [42]. In our extensive review of the literature, several articles did not provide data by age or bacteremia status [36, 43, 44], several provided data by age alone [18, 25, 27, 28, 45–47], and several provided data by bacteremia status alone [17, 18, 45–48]. Fortunately, 10 articles provided data by age and bacteremia status simultaneously [19–22, 24, 26, 49–52].…”

Section: Estimates Of Effectiveness For Potential Active Control Regimentioning

confidence: 99%

Issues in Noninferiority Trials: The Evidence in Community‐Acquired Pneumonia

Fleming

Powers

2008

CLIN INFECT DIS

View full text Add to dashboard Cite

When investigators hypothesize that experimental interventions provide advantages other than improved effectiveness, they can use noninferiority (NI) trials to determine whether one can rule out the possibility that those interventions have unacceptably worse effectiveness than the standard "active control" regimen. To conduct valid NI trials, there must be evidence from historical studies that provides reliable, reproducible, and precise estimates of the effect of the active control, compared with that of placebo, on the specific outcomes investigators plan to use in the NI trial; this effect should be of substantial magnitude, and the estimates of the active control's effect from historical studies must represent its effect in the planned NI trial had a placebo group been included. These conditions allow formulation of an NI margin such that, if the NI trial establishes that the effectiveness of the experimental intervention is not worse than the effectiveness of the active control by more than the NI margin, then one can conclude that the experimental regimen (1) preserves a substantial fraction of the effect of the active control and (2) will not result in a clinically meaningful loss of effectiveness. After general discussion of NI trial design issues, we consider the design of NI trials to evaluate antimicrobials in the treatment of community-acquired pneumonia. We present an extensive literature review, allowing estimation of the historical effect of active control regimens in community-acquired pneumonia primarily on the basis of evidence related to use of sulfonamides or penicillin. This review allows formulation of NI margins that are specific to age and bacteremia status of patients.When effective interventions are available to treat or prevent a disease, there are instances in which investigators are interested in evaluating new experimental agents because they hypothesize that these agents provide advantages other than enhancing effectiveness. For instance, in the treatment of invasive aspergillosis, voriconazole may provide a better adverseReprints or correspondence: Dr. Thomas R. Fleming, Dept. of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195 (E-mail: tfleming@u.washington.edu).. The content of this publication does not necessarily reflect the views or policies of the US Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. Potential conflicts of interest. T.R.F. has received consulting fees from Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, Roche, Schering-Plough, Theravance, and Wyeth; interactions with these companies were not on projects related to communityacquired pneumonia. J.H.P. has received consulting fees from Acureon, Astellas, Astra-Zeneca, Basilea, Centegen, Cerexa, Concert, Cubist, Destiny, Forest, Johnson & Johnson, Merck, Methylgene, MPEX, Octoplus, Takeda, Theravance, and Wyeth. NIH Public Access Author Manu...

show abstract

Section: Estimates Of Effectiveness For Potential Active Control Regimentioning

confidence: 99%

Issues in Noninferiority Trials: The Evidence in Community‐Acquired Pneumonia

Fleming

Powers

2008

CLIN INFECT DIS

View full text Add to dashboard Cite

show abstract

“…This high figure cannot be compared with any obtained from an average series of pneumonias, as many cases were referred because the illness was in some measure atypical. It has been affirmed by Davies et al (1935) and Morgan and Wylie-Smith (1943) that delayed resolution is commoner in the older age groups. Their belief was not sustained by this investigation, in which four were below the age of 15, eight above 40, and the remaining 17 spread evenly between these ages.…”

Section: Classification Of Casesmentioning

confidence: 95%